{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:57:05Z","timestamp":1787014625629,"version":"build-2736575974"},"reference-count":158,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,6,4]],"date-time":"2010-06-04T00:00:00Z","timestamp":1275609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Although treatment of drug\u2010susceptible tuberculosis (TB) under ideal conditions may be successful in \u226595% of cases, cure rates in the field are often significantly lower due to the logistical challenges of administering and properly supervising the intake of combination chemotherapy for 6\u20139\u2003months. Success rates are far worse for multidrug\u2010resistant and extensively drug\u2010resistant TB cases. There is general agreement that new anti\u2010TB drugs are needed to shorten or otherwise simplify treatment for drug\u2010susceptible and multidrug\u2010resistant\/extensively drug\u2010resistant\u2010TB, including TB associated with HIV infection. For the first time in over 40\u2003years, a nascent pipeline of new anti\u2010TB drug candidates has been assembled. Eleven candidates from seven classes are currently being evaluated in clinical trials. They include novel chemical entities belonging to entirely new classes of antibacterials, agents approved for use against infections other than TB, and an agent already approved for limited use against TB. In this article, we review the current state of TB treatment and its limitations and provide updates on the status of new drugs in clinical trials. In the conclusion, we briefly highlight ongoing efforts to discover new compounds and recent advances in alternative drug delivery systems.<\/jats:p>","DOI":"10.1111\/j.1440-1843.2010.01775.x","type":"journal-article","created":{"date-parts":[[2010,6,4]],"date-time":"2010-06-04T06:12:19Z","timestamp":1275631939000},"page":"764-778","source":"Crossref","is-referenced-by-count":60,"title":["Current development and future prospects in chemotherapy of tuberculosis"],"prefix":"10.1111","volume":"15","author":[{"given":"Eric L.","family":"NUERMBERGER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin K.","family":"SPIGELMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Wai","family":"YEW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,21]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox W","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_3_2","volume-title":"Global Tuberculosis Control: Epidemiology, Planning, Financing: WHO Report 2009","author":"World Health Organization","year":"2009"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/505877"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068273"},{"key":"e_1_2_7_6_2","volume-title":"Treatment of Tuberculosis: Guidelines for National Programmes","author":"World Health Organization","year":"2003"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200605-637OC"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09742-8"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2005.02.002"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2007.01180.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.19.2537"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328319bce6"},{"key":"e_1_2_7_13_2","volume-title":"Guidelines for the Programmatic Management of Drug\u2010Resistant Tuberculosis","author":"World Health Organization","year":"2006"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.3.744"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040292"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01751.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.11.887"},{"key":"e_1_2_7_18_2","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Centers for Disease Control and Prevention and American Thoracic Society","year":"2000","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_2_7_19_2","volume-title":"Canadian Tuberculosis Standards","author":"Long R","year":"2007"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0153OC"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/520983"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/143.4_Pt_1.707"},{"key":"e_1_2_7_23_2","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.7.536"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.11.1445"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06532-X"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200512-1953OC"},{"key":"e_1_2_7_28_2","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug\u2010resistant tuberculosis","volume":"167","author":"Papastavros T","year":"2002","journal-title":"CMAJ"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(21)00072-1"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/29.5.477"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200504-613PP"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00566-08"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01621-06"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00554-08"},{"key":"e_1_2_7_36_2","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison DA","year":"2000","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.2.115"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S440"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199911000-00001"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_2_7_42_2","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani A","year":"1980","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-06"},{"key":"e_1_2_7_44_2","first-page":"161","article-title":"A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis","volume":"43","author":"Kochar DK","year":"2006","journal-title":"J. Vector Borne Dis."},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2061"},{"key":"e_1_2_7_46_2","first-page":"S63","article-title":"Low doses of rifapentine versus high doses of rifampin in the mouse model of tuberculosis","volume":"12","author":"Grosset JH","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/141.3.626"},{"key":"e_1_2_7_48_2","first-page":"437","article-title":"Single and multiple dose pharmacokinetics of rifapentine in man: part II","volume":"3","author":"Keung A","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_49_2","first-page":"862","article-title":"Consecutive\u2010dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis","volume":"8","author":"Langdon G","year":"2004","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_50_2","first-page":"3","article-title":"Rifapentine and isoniazid in the continuation phase of a 6\u2010month regimen. Final report at 5\u2003years: prognostic value of various measures","volume":"6","author":"Tam CM","year":"2002","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11467-8"},{"key":"e_1_2_7_52_2","author":"Anonymous","year":"1998","journal-title":"Rifapentine (Priftin) Data on File [Package Insert]"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200201-047OC"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200411-1557OC"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200602-280OC"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200807-1029OC"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040344"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0795OC"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2066"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.783-785.2003"},{"key":"e_1_2_7_62_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.43.1.85","article-title":"Moxifloxacin (BAY12\u20108039), a new 8\u2010methoxyquinolone, is active in a mouse model of tuberculosis","volume":"43","author":"Miyazaki E","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200305-682OC"},{"key":"e_1_2_7_64_2","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson JL","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.780-782.2004"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3117-3122.2003"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60559-6"},{"key":"e_1_2_7_68_2","volume-title":"Guidelines for the Programmatic Management of Drug\u2010Resistant Tuberculosis: Emergency Update","author":"World Health Organization","year":"2008"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200310-1380OC"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-885OC"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-360OC"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60333-0"},{"key":"e_1_2_7_73_2","first-page":"128","article-title":"A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee R","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0078OC"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"e_1_2_7_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio884"},{"key":"e_1_2_7_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01611-09"},{"key":"e_1_2_7_78_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M803899200"},{"key":"e_1_2_7_79_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711697105"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"e_1_2_7_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-07"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00898-06"},{"key":"e_1_2_7_83_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200807-1152OC"},{"key":"e_1_2_7_84_2","doi-asserted-by":"crossref","unstructured":"IbrahimM Truffot\u2010PernotC AndriesKet\u2003al.Sterilizing activity of a second line regimen including R207910 (TMC207) in murine tuberculosis. Abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting 51. 2008.","DOI":"10.1128\/AAC.00898-06"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61204-0"},{"key":"e_1_2_7_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00973-08"},{"key":"e_1_2_7_87_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200808-1333ED"},{"key":"e_1_2_7_88_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1736OC"},{"key":"e_1_2_7_89_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.2.183"},{"key":"e_1_2_7_90_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"e_1_2_7_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/35016103"},{"key":"e_1_2_7_92_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164571"},{"key":"e_1_2_7_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-9792(08)70017-9"},{"key":"e_1_2_7_94_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508392103"},{"key":"e_1_2_7_95_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.184.9.2420-2428.2002"},{"key":"e_1_2_7_96_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.24.7058-7066.2001"},{"key":"e_1_2_7_97_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2294-2301.2005"},{"key":"e_1_2_7_98_2","first-page":"69","article-title":"Comparison of the sterilising activities of the nitroimidazopyran PA\u2010824 and moxifloxacin against persisting Mycobacterium tuberculosis","volume":"12","author":"Hu Y","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2289-2293.2005"},{"key":"e_1_2_7_100_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00451-06"},{"key":"e_1_2_7_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00686-08"},{"key":"e_1_2_7_102_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00074-08"},{"key":"e_1_2_7_103_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00106-09"},{"key":"e_1_2_7_104_2","unstructured":"GinsbergA DiaconA DawsonRet\u2003al.Extended early bactericidal activity (EBA) of PA\u2010824 a novel drug for tuberculosis treatment. Final Program of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting 315. 2008."},{"key":"e_1_2_7_105_2","unstructured":"AhmadZ PeloquinC TyagiSet\u2003al.PA\u2010824 exhibits time\u2010dependent bactericidal activity in a murine tuberculosis model. Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009."},{"key":"e_1_2_7_106_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki319"},{"key":"e_1_2_7_107_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl227"},{"key":"e_1_2_7_108_2","unstructured":"ReddyVM EinckL AndriesKet\u2003al.The new antitubercular drugs SQ109 and TMC207 act synergistically in vitro to killMycobacterium tuberculosis. Abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting 145\u2010146. 2008."},{"key":"e_1_2_7_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705984"},{"key":"e_1_2_7_110_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01326-06"},{"key":"e_1_2_7_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706650"},{"key":"e_1_2_7_112_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.416-417.2003"},{"key":"e_1_2_7_113_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1189"},{"key":"e_1_2_7_114_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.360-362.2003"},{"key":"e_1_2_7_115_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1988"},{"key":"e_1_2_7_116_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki148"},{"key":"e_1_2_7_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.06.014"},{"key":"e_1_2_7_118_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl298"},{"key":"e_1_2_7_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.04.007"},{"key":"e_1_2_7_120_2","first-page":"345","article-title":"Linezolid in the treatment of \u2018difficult\u2019 multidrug\u2010resistant tuberculosis","volume":"12","author":"Yew WW","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_121_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00009509"},{"key":"e_1_2_7_122_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp171"},{"key":"e_1_2_7_123_2","doi-asserted-by":"publisher","DOI":"10.1086\/648675"},{"key":"e_1_2_7_124_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp291"},{"key":"e_1_2_7_125_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00111009"},{"key":"e_1_2_7_126_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200806-892OC"},{"key":"e_1_2_7_127_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm950956y"},{"key":"e_1_2_7_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.01.021"},{"key":"e_1_2_7_129_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4351-4353.2005"},{"key":"e_1_2_7_130_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01182-08"},{"key":"e_1_2_7_131_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200904-0611OC"},{"key":"e_1_2_7_132_2","unstructured":"KumarV JakubiecW LiWet\u2003al.Safety tolerability PK and whole blood bactericidal activity (WBA) againstMycobacterium tuberculosisof single ascending doses of PNU\u2010100480. Final Program of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 219. 2009."},{"key":"e_1_2_7_133_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1965.91.1.117"},{"key":"e_1_2_7_134_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.27629-0"},{"key":"e_1_2_7_135_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi701506h"},{"key":"e_1_2_7_136_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2620"},{"key":"e_1_2_7_137_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1167498"},{"key":"e_1_2_7_138_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.24.3.429"},{"key":"e_1_2_7_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(95)90588-X"},{"key":"e_1_2_7_140_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.4.1025"},{"key":"e_1_2_7_141_2","doi-asserted-by":"publisher","DOI":"10.1086\/513945"},{"key":"e_1_2_7_142_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540152029954"},{"key":"e_1_2_7_143_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2816-2821.2005"},{"key":"e_1_2_7_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(92)90145-A"},{"key":"e_1_2_7_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.08.015"},{"key":"e_1_2_7_146_2","doi-asserted-by":"publisher","DOI":"10.1086\/590064"},{"key":"e_1_2_7_147_2","unstructured":"Anonymous.Antibiotic combination defeats extensively drug\u2010resistant TB. 2\u201027\u20102009. ScienceDaily. 1\u20106\u20100010."},{"key":"e_1_2_7_148_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.3035"},{"issue":"11","key":"e_1_2_7_149_2","first-page":"S29","article-title":"Eradication of Mycobacterium tuberculosis infection in 2\u2003months with LL\u20103858: a preclinical study","volume":"8","author":"Arora S","year":"2004","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_7_150_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-118"},{"key":"e_1_2_7_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2003.07.001"},{"key":"e_1_2_7_152_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh260"},{"key":"e_1_2_7_153_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010061013365"},{"key":"e_1_2_7_154_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2682"},{"key":"e_1_2_7_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(98)00116-1"},{"key":"e_1_2_7_156_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.833-836.2003"},{"key":"e_1_2_7_157_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki027"},{"key":"e_1_2_7_158_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9381-6"},{"key":"e_1_2_7_159_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01164-06"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1843.2010.01775.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1843.2010.01775.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:53:13Z","timestamp":1697259193000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1843.2010.01775.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,21]]},"references-count":158,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1440-1843.2010.01775.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1843.2010.01775.x","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,21]]}}}